Chinese medicine concept stocks continued to rise, many stocks rose and stopped

Pharmaceutical Network Industry Dynamics: In the capital market in 2020, chinese medicine concept stocks can be said to be a unique landscape.
and the previous disclosure, for investors to understand the development of Chinese medicine stocks behind the development of enterprises provides a good opportunity.
data show that the current 97 Chinese medicine concept shares, in order of the net profit growth rate attributable to shareholders of the parent company, the indicator can be found that 32 companies have different degrees of growth year-on-year, and 6 achieved net profit growth of more than 1 times year-on-year.
, Yunnan white medicine net profit amount is higher.
from public information, it is clear that in the first half of 2020, it achieved operating income of 15.493 billion yuan, a net increase of 1.596 billion yuan, or 11.48 percent, from 13.897 billion yuan a year earlier; Net income attributable to shareholders of listed companies increased by RMB351 million, or 14.18%, to RMB2,454 million, or 9.20%, from RMB2,247 million a year earlier.
addition, 39 other companies have net profit attributable to shareholders of the parent company of more than 100 million yuan.
, the industry generally believes that the current macro-policy to the field of industry practice are encouraging the development of the Chinese medicine industry required supporting research and development, service business, so in this context, the Chinese medicine industry is expected to usher in a period of development opportunities.
, from the recent development trend of Chinese medicine concept unit, we can see that the development momentum of the Chinese medicine industry is better, and has received high attention in the capital market.
afternoon, the concept of Chinese medicine stocks on the phenomenon of a move higher, including Xiang Xue Pharmaceutical, Xinguang Pharmaceuticals, Baiyunshan 3 stocks rose and stopped.
according to public information, today Xiang Xue Pharmaceutical opened at 10.91 yuan, as of 13:44, the stock rose 20.02% to 12.89 yuan, closed the board.
it is learned that Xiang Xue Pharmaceutical is mainly engaged in the development, production and sale of modern Chinese medicine and Chinese medicine tablets, supplemented by medical equipment, soft drinks, a small number of Western medicine products and pharmaceutical circulation business.
as of June 30, 2020, Xiang Xue Pharmaceutical's operating income was RMB1,816.46 million, and net income attributable to shareholders of the parent company was RMB141.14 million, an increase of 152.4695 percent year-on-year and a basic earnings per share of RMB0.21.
Xinguang Pharmaceuticals opened at 19.21 yuan, as of 10:49, the stock rose 19.98 percent to 23.3 yuan, closed the board.
Xinguang Pharmaceuticals is mainly engaged in the research and development, production and marketing of Chinese medicine, chemical drugs and health food.
as of June 30, 2020, Xinguang Pharmaceuticals' operating income was RMB128.43 million, and net income attributable to shareholders of the parent company was RMB46,020.948 million, an increase of 6.5374 percent year-on-year and a basic earnings per share of RMB0.29.
Baiyunshan on the 16th, also opened high, the afternoon volume rose and stopped, the stock reported 34.18 yuan, sealed more than 44,000 hands.
, Baiyunshan Hong Kong shares also rose sharply, as of the release, the stock rose more than 15%.
it is understood that Baiyunshan's main business for Chinese medicine, chemical medicine and biopharmaceuticals as one of the pharmaceutical manufacturing, pharmaceutical trade and large health products research and development, production and sales.
in the past six months, two brokerages have given buying advice.
In addition, there are many Chinese medicine enterprises are also performing well, such as Ji Pharmaceutical Holdings, Zoellick Pharmaceuticals, Guizhou Sanli, Red Day Pharmaceuticals, Foci Pharmaceuticals, Weikang Pharmaceuticals, etc. have also seen varying degrees of rise.
Overall, the pharmaceutical industry will be a long-term investment, capital continued to pay attention to the field, and benefit from the pharmaceutical market benefits, as well as related policies to support the development of the Chinese medicine industry, the strength of the Chinese medicine stocks will also be a long-term optimistic investment and financing field.